As of 2024-12-13, the EV/EBITDA ratio of Arrowhead Pharmaceuticals Inc (ARWR) is -5.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARWR's latest enterprise value is 3,046.44 mil USD. ARWR's TTM EBITDA according to its financial statements is -584.23 mil USD. Dividing these 2 quantities gives us the above ARWR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 15.9x | 15.6x |
| Forward P/E multiples | 15.6x - 24.3x | 17.8x |
| Fair Price | (75.77) - (77.27) | (80.85) |
| Upside | -442.2% - -449.0% | -465.2% |
| Date | EV/EBITDA |
| 2024-12-11 | -5.49 |
| 2024-12-10 | -5.59 |
| 2024-12-09 | -5.45 |
| 2024-12-06 | -5.53 |
| 2024-12-05 | -5.25 |
| 2024-12-04 | -5.42 |
| 2024-12-03 | -6.05 |
| 2024-12-02 | -6.11 |
| 2024-11-29 | -6.04 |
| 2024-11-27 | -6.07 |
| 2024-11-26 | -4.98 |
| 2024-11-25 | -4.50 |
| 2024-11-22 | -4.45 |
| 2024-11-21 | -4.39 |
| 2024-11-20 | -4.48 |
| 2024-11-19 | -4.46 |
| 2024-11-18 | -4.55 |
| 2024-11-15 | -4.45 |
| 2024-11-14 | -5.06 |
| 2024-11-13 | -5.11 |
| 2024-11-12 | -5.08 |
| 2024-11-11 | -5.18 |
| 2024-11-08 | -5.16 |
| 2024-11-07 | -5.05 |
| 2024-11-06 | -5.04 |
| 2024-11-05 | -4.88 |
| 2024-11-04 | -4.77 |
| 2024-11-01 | -4.65 |
| 2024-10-31 | -4.60 |
| 2024-10-30 | -4.70 |
| 2024-10-29 | -4.75 |
| 2024-10-28 | -4.80 |
| 2024-10-25 | -4.78 |
| 2024-10-24 | -4.74 |
| 2024-10-23 | -4.74 |
| 2024-10-22 | -4.84 |
| 2024-10-21 | -4.86 |
| 2024-10-18 | -5.01 |
| 2024-10-17 | -4.94 |
| 2024-10-16 | -4.99 |
| 2024-10-15 | -4.73 |
| 2024-10-14 | -4.62 |
| 2024-10-11 | -4.43 |
| 2024-10-10 | -4.27 |
| 2024-10-09 | -4.30 |
| 2024-10-08 | -4.34 |
| 2024-10-07 | -4.36 |
| 2024-10-04 | -4.51 |
| 2024-10-03 | -4.51 |
| 2024-10-02 | -4.59 |